Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
As the global plasmid market continues to grow rapidly, current and projected demand for high quality plasmid continues to be challenged by the availability of global supply. Thermo Fisher’s clinical and commercial capabilities support the manufacture of cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies including life-saving cancer treatments as well as mRNA vaccines.
Learn more about cGMP plasmid DNA capabilities by downloading our portfolio fact sheet.